These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1319 related items for PubMed ID: 15104559

  • 1. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 2. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 3. [Long-term effects of 7-year growth hormone substitution on bone metabolism, bone density, and bone quality in growth hormone-deficient adults].
    Wilhelm B, Kann PH.
    Med Klin (Munich); 2004 Oct 15; 99(10):569-77. PubMed ID: 15490072
    [Abstract] [Full Text] [Related]

  • 4. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PG.
    Growth Horm IGF Res; 2008 Aug 15; 18(4):318-24. PubMed ID: 18289903
    [Abstract] [Full Text] [Related]

  • 5. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 15; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May 15; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 7. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P, Bruckner T, Hosch S, Haass M, Klar E, Sauer P, Ziegler R, Leidig-Bruckner G.
    Osteoporos Int; 2003 Jan 15; 14(1):82-9. PubMed ID: 12577189
    [Abstract] [Full Text] [Related]

  • 8. Effect of long-term growth hormone treatment on bone mass and bone metabolism in growth hormone-deficient men.
    Bravenboer N, Holzmann PJ, ter Maaten JC, Stuurman LM, Roos JC, Lips P.
    J Bone Miner Res; 2005 Oct 15; 20(10):1778-84. PubMed ID: 16160735
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term effects of growth hormone (GH) on bone mineral status and bone turnover markers in patients with isolated GH deficiency and multiple pituitary hormone deficiency.
    Gonc EN, Kandemir N.
    Clin Endocrinol (Oxf); 2007 May 15; 66(5):672-7. PubMed ID: 17381489
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I, Vignau J, Collier F, Cortet B.
    Calcif Tissue Int; 2008 Nov 15; 83(5):315-23. PubMed ID: 18836675
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 15; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 20. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
    Jiang Y, Li M, Xia W, Xing X, Yu W, Tian J, Meng X, Zhou X.
    Zhonghua Yi Xue Za Zhi; 2002 Sep 25; 82(18):1254-6. PubMed ID: 12425805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.